查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1189820

抗生物膜伤口敷料市场—增长、趋势、COVID-19 影响和预测2023-2028

Anti-Biofilm Wound Dressing Market - Growth, Trends, and Forecasts (2023- 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，抗生物膜伤口敷料市场的复合年增长率预计为 9.5%。

主要亮点

  • COVID-19 大流行对抗生物膜伤口敷料市场产生了重大影响，因为大多数医疗机构都忙于管理 COVID-19 患者。 在封锁的早期阶段，择期手术被推迟，严重影响了伤口护理管理。 据报导，在封锁期间，患者就诊人数显着减少。 根据德国慕尼黑 Ludwig-Maximilians-Universitat 进行的一项研究，由于大流行，约 23% 的慢性伤口患者无法就医。 此外，约有 10% 的人表示他们避免去看医生以进行预防。
  • 越来越多地使用远程医疗来管理慢性和急性伤口，导致市场强劲復苏。 各种医疗保健提供者已经开发了远程医疗平台，以有效地管理患有急性和慢性伤口的患者。 例如，2021 年 1 月，Wound Pros Inc. 开发了一个远程医疗平台，用于患者和专业人员之间的交流。 该供应商还发明了一款名为“RITA”的应用程序，可帮助进行新的诊断和伤口测量。
  • 慢性疾病（糖尿病、静脉疾病、动脉疾病等）造成的未癒合伤口会在伤口表面出现一层细菌污染膜。 预计慢性和急性伤口病例的增加将在预测期内推动市场增长。 美国国家生物技术信息中心2022年6月发表的一项研究发现，全球压疮患病率接近12.8%，其中医院获得性压疮（HAPI）占8.4%。
  • 此外，全球新兴国家医疗保健基础设施的发展、伤口管理领域的技术发展以及领先公司和医疗保健专业人员为提高伤口护理意识所做的共同努力也在推动市场增长。我们支持增长。 例如，2022 年 2 月，Asep Medical Holdings Inc. 宣布与美国陆军医学研究和材料司令部合作开发的抗生物膜/抗炎□技术取得积极成果。
  • 这些是预计在不久的将来推动对先进伤口敷料解决方案（包括抗生物膜产品）的需求的主要因素。 然而，与伤口护理相关的高成本和熟练专业人员的短缺预计将阻碍市场增长。

主要市场趋势

化工板块预计在预测期内将显着增长

  • 化学抗生物膜敷料领域预计将实现强劲增长，这是由于碘和离子银产品的主要参与者以及慢性病患者数量的增加。 此外，该细分市场主要参与者推出创新产品也是化学抗生物膜敷料产品占据较大市场份额的原因。 例如，2020 年 11 月，Sanara MedTech 在市场上推出了 BIAKOS 抗菌皮肤和伤口清洁剂。 临床研究表明，该产品在使用后 72 小时内即可破坏生物膜微生物。
  • 由于糖尿病等疾病的激增，慢性伤口（静脉性腿部溃疡、压力性溃疡、糖尿病性腿部溃疡等）的增加也推动了该行业的发展。 根据国际糖尿病联合会的数据，到 2021 年，全球将有超过 5.37 亿成年人患有糖尿病。 到 2030 年底，这一数字预计将超过 6.4 亿。 根据发表在 Healogics 上的一篇文章，大约有 700 万美国人患有慢性伤口，大流行期间截肢人数增加了 50%。
  • 因此，由于创新产品的推出和慢性伤口的日益流行，预计化学抗生物膜伤口敷料部分在预测期内将呈现显着增长。

预计北美将主导抗生物膜伤口敷料市场

  • 由于技术先进的产品随时可用以及该地区伤口护理诊所数量不断增加等因素，预计北美将主导该市场。 在美国医院和门诊手术中心等医疗设施中越来越多地使用先进产品是促进北美研究市场增长的关键因素之一。 该地区有 3M、B. Braun SE、Convatec Inc.、SmithplusNephew 和 Coloplast Corp 等主要市场参与者，有利的报销政策也有望推动市场。
  • 伤口处理（包括压疮）支出的增加也在推动市场增长。 根据美国医疗保健研究与质量署发表的一篇论文，每年约有 250 万患者患有压疮，在美国，治疗单个患者的费用从每名患者 20,900 美元到 151,700 美元不等，并且不断增加。
  • 此外，该地区发达的基础设施和美国交通事故的增加也推动了该地区的市场增长。 据美国国家公路交通安全管理局称，美国的交通事故数量持续上升。 到 2021 年，道路交通事故将导致超过 42,000 人死亡，与 2020 年报告的 38,824 人死亡相比增加了 10.5%。
  • 由于主要市场参与者的存在、伤口管理支出增加以及交通事故增加等因素，预计美国抗生物膜伤口敷料市场将在北美出现显着增长。

竞争格局

由于多家公司在全球和区域开展业务，因此抗生物膜伤口敷料市场较为分散。

竞争格局包括 Convatec Inc.、SmithplusNephew、URGO、Coloplast Corp.、3M、B. Braun SE、Molnlycke Health Care AB、Imbed Biosciences、Medline Industries LP 和 Integra LifeSciences，这些公司拥有重要的市场份额。包括分析少数知名的国际和本地公司。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 慢性伤口的患病率增加
    • 先进伤口护理创新产品的介绍
    • 手术次数增加
  • 市场製约因素
    • 高产品成本和替代品的使用增加
  • 行业吸引力 - 波特五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模:百万美元）

  • 按机制
    • 体检
    • 化学
    • 生物作用
  • 按伤口类型
    • 慢性伤口
      • 糖尿病足溃疡
      • 压疮
      • 下肢静脉溃疡
      • 其他慢性伤口
    • 急性伤口
  • 最终用户
    • 医院和诊所
    • 手术中心
    • 其他最终用户
  • 按地区细分
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Convatec Inc.
    • SmithplusNephew
    • URGO
    • Coloplast Corp.
    • 3M
    • B. Braun SE
    • Molnlycke Health Care AB
    • Imbed Biosciences
    • Medline Industries, LP
    • Integra LifeSciences

第7章 市场机会与今后动向

简介目录
Product Code: 93225

The anti-biofilm wound dressing market is expected to register a CAGR of 9.5% over the forecast period.

Key Highlights

  • The COVID-19 pandemic had a significant impact on the anti-biofilm wound dressing market as the majority of the healthcare facilities were occupied with the management of COVID-19 patients. The elective procedures were postponed during the initial phase of the lockdown, which significantly impacted wound care management. The number of patient visits reported a substantial decline during the lockdown period. According to a study conducted by Ludwig Maximilian University, Munich, Germany, around 23% of patients suffering from chronic wounds were not able to visit physicians due to the pandemic. Moreover, around 10% of respondents avoided doctor visits as a precaution.
  • The increased use of telehealth in the management of chronic and acute wounds was responsible for the strong recovery of the market. Various healthcare providers developed telehealth platforms in order to effectively manage patients suffering from acute and chronic wounds. For instance, in January 2021, Wound Pros Inc. developed a telehealth platform for communication between patients and professionals. The provider also invented an app named "RITA," which helps in new diagnostic and wound measurement.
  • The unhealed wounds caused by chronic diseases (such as diabetes, venous, or arterial disorders) show bacterial contamination film on the wound surface. The growing cases of chronic and acute wounds are expected to drive the growth of the market during the forecast period. According to the research published by National Center for Biotechnology Information in June 2022, the global prevalence of pressure ulcers is close to 12.8%, with hospital-acquired pressure injury (HAPI) accounting for 8.4% of patients.
  • Moreover, the evolving healthcare infrastructure in developing countries across the globe, technological advancements in the field of wound management, and combined initiatives taken by key players and healthcare providers to increase awareness about wound care are also supporting the market's growth. For instance, in February 2022, Asep Medical Holdings Inc. announced positive outcomes related to the Antibiofilm/Anti-inflammatory Peptide Technology developed with the help of United States Army Medical Research and Materiel Command.
  • These are the key factors expected to drive the demand for advanced wound dressing solutions, including anti-biofilm products, in the near future. However, high costs associated with wound care treatment, along with the scarcity of skilled professionals, are anticipated to impede the growth of the market.

Key Market Trends

Chemical Segment is Expected to Witness Significant Growth Over the Forecast Period

  • The chemical anti-biofilm dressing segment is anticipated to register significant growth owing to the presence of key players in the segment with iodine and ionic silver-based products, along with the rising number of patients suffering from chronic diseases. Moreover, the introduction of innovative products by major players in this segment is also responsible for the significant share of chemical anti-biofilm dressing products in the market. For instance, in November 2020, Sanara MedTech launched BIAKOS Antimicrobial Skin and Wound Cleanser in the market. The clinical studies revealed that after the application of the product, it disrupted biofilm microbes within 72 hours.
  • The increasing prevalence of chronic wounds (like venous leg ulcers, pressure ulcers, and diabetic foot ulcers) due to a surge in the prevalence of medical conditions such as diabetes is also augmenting the growth of the segment. According to the International Diabetes Federation, in 2021, more than 537 million adults were suffering from diabetes across the world. The number is likely to surpass 640 million by the end of 2030. According to the article published in Healogics, around 7 million Americans are living with a chronic wound, and it indicated an increase of 50% in amputations during the pandemic.
  • Therefore, the chemical anti-biofilm dressing segment is expected to witness significant growth over the forecast period due to the introduction of innovative products and the increasing prevalence of chronic wounds.

North America is Expected to Dominate the Anti-Biofilm Wound Dressing Market

  • North America is expected to dominate the market owing to factors such as the easy availability of technologically advanced products and the increasing number of wound care clinics in the region. An increase in the usage of advanced products in the healthcare facilities, such as hospitals and ambulatory surgical centers in United States, is among the key factors which contribute to the growth of the market studied in North America. The presence of key market players such as 3M, B. Braun SE, Convatec Inc., Smith+Nephew, and Coloplast Corp in the region, along with favorable reimbursement policies, are also anticipated to drive the market.
  • Increasing expenditure on the management of wounds, including pressure ulcers, is also driving the growth of the market. According to the article published by the Agency for Healthcare Research and Quality, every year, around 2.5 million patients suffer from pressure ulcers, and the cost of individual patient care ranges from USD 20,900-151,700 per patient in United States.
  • The well-developed infrastructure in the region and the increasing number of road accidents in United States are also propelling the growth of the market in the region. According to the National Highway Traffic Safety Administration, the number of road accidents is continuously increasing in United States. Road accidents were responsible for more than 42,000 fatalities in 2021, which reflects a 10.5% increase as compared to 38,824 fatalities reported in 2020.
  • Owing to the factors such as the presence of key market players, increasing expenditure on wound management, and increasing number of road accidents, the US anti-biofilm wound dressing market is anticipated to show significant growth in North America.

Competitive Landscape

The anti-biofilm wound dressing market is moderately fragmented in nature due to the presence of several companies operating globally and regionally.

The competitive landscape includes an analysis of a few international as well as local companies which hold large market shares and are well known, including Convatec Inc., Smith+Nephew, URGO, Coloplast Corp., 3M, B. Braun SE, Molnlycke Health Care AB, Imbed Biosciences, Medline Industries LP, and Integra LifeSciences, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Wounds
    • 4.2.2 Introduction of Innovative Products in Advanced Wound Care
    • 4.2.3 Surge in the Number of Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Product Cost Along with the Increasing Utilization of Substitutes
  • 4.4 Industry Attractiveness - Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Mechanism
    • 5.1.1 Physical
    • 5.1.2 Chemical
    • 5.1.3 Biological
  • 5.2 By Wound Type
    • 5.2.1 Chronic Wounds
      • 5.2.1.1 Diabetic Foot Ulcers
      • 5.2.1.2 Pressure Ulcers
      • 5.2.1.3 Venous Leg Ulcers
      • 5.2.1.4 Other Chronic Wounds
    • 5.2.2 Acute Wounds
  • 5.3 By End User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Convatec Inc.
    • 6.1.2 Smith+Nephew
    • 6.1.3 URGO
    • 6.1.4 Coloplast Corp.
    • 6.1.5 3M
    • 6.1.6 B. Braun SE
    • 6.1.7 Molnlycke Health Care AB
    • 6.1.8 Imbed Biosciences
    • 6.1.9 Medline Industries, LP
    • 6.1.10 Integra LifeSciences

7 MARKET OPPORTUNITIES AND FUTURE TRENDS